Business
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationaleChronic Pouchitis offers a capital-efficient rare-disease path with fast route to marketHidradenitis Suppurativa enables rapid proof-of-concept in a large dermatology marketFirst Phase 2 clinical trial expected to start in H2 2026, subject to financingUlcerative Colitis remains a key indication to be partnered Nantes, France,
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab","length":118,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Development built on strong IL-7R biological rationale","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"Chronic Pouchitis offers a capital-efficient rare-disease path with fast route to market","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Hidradenitis Suppurativa enables rapid proof-of-concept in a large dermatology market","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"First Phase 2 clinical trial expected to start in H2 2026, subject to financing","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Ulcerative Colitis remains a key indication to be partnered","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":365,"olType":false},{"type":"text","content":"Nantes, France, January 29, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the selection of two new clinical indications for lusvertikimab (OSE-127): chronic pouchitis and hidradenitis suppurativa (HS). These indications were chosen based on strong, IL-7R-driven biology and are fully aligned with the Company’s 2026–2028 strategic plan to expand lusvertikimab into targeted, high value immune-mediated diseases. Development of one or both indications will proceed subject to financing, with the first Phase 2 clinical trial planned to initiate in H2 2026.","length":605,"tagName":"p"},{"type":"text","content":"A Science-Led Selection of Two High-Value Indications with Significant Unmet Medical Need","length":89,"tagName":"p"},{"type":"text","content":"Chronic pouchitis and HS both exhibit robust translational alignment with IL...